Inogen, Inc. (INGN Quick QuoteINGN - Free Report) is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and macroeconomic conditions remains a key risk.

This Zacks Rank #3 (Hold) company’s shares have gained 0.6% in the year-to-date period against the industry’s 16.1% decline. However, the S&P 500 has risen 7.4% during the same timeframe.

The renowned provider of POCs has a market capitalization of $177.1 million. The company projects 10.5% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.5 compared with the industry’s 2.3 makes its valuation attractive.

Image Source: Zacks Investment Research

Let’s delve deeper.

Factors Driving INGN’s Prospects

Strong Positioning in the Expanding Home Oxygen Market: POCs remain Inogen’s core business and continue benefiting from the growing shift toward home-based respiratory care. Management estimates that approximately 60% of new long-term oxygen therapy (LTOT) patients now begin treatment with a POC, compared with less than 40% a few years ago. This transition supports strong B2B demand and the broader industry migration away from traditional oxygen tanks and cylinders. Inogen is well positioned to capitalize on rising demand through its established relationships with home medical equipment (HME) providers and respiratory specialists.

Expanding Product Portfolio Creates New Revenue Opportunities: Inogen is broadening its presence across adjacent respiratory care markets, including sleep therapy and airway clearance. Recent launches such as the Aurora CPAP mask family and growing adoption of Voxi 5 are creating cross-selling opportunities within the company’s existing HME network. In addition, Inogen continues to advance Simeox, an airway clearance technology targeting a sizable non-cystic fibrosis bronchiectasis market, further diversifying its growth drivers beyond oxygen therapy.

International Expansion Accelerating Growth: International markets are becoming an important growth engine. In first-quarter 2026, international revenues increased 18% year over year, supported by strong execution, expanding HME partnerships and geographic expansion across Eastern Europe, Latin America and Asia-Pacific. The launch of the Rove 6 portable oxygen concentrator in Brazil highlights Inogen’s efforts to capitalize on growing global demand for home oxygen therapy, particularly in underpenetrated respiratory care markets.

INGN: Key Risks to Watch

Pressure on Direct-to-Consumer and Rental Revenues: Inogen's U.S. direct-to-consumer (DTC) and rental businesses continue to face headwinds as portable oxygen concentrators (POCs) are becoming the standard first-line therapy. This reduces the need for patients to switch from traditional oxygen tanks, historically a key driver of DTC demand. In the first quarter of 2026, U.S. sales declined 5% year over year, and rental revenues fell 8%. Management expects this mix shift to continue through 2026, potentially limiting growth and operating leverage in the direct channel.

Reimbursement and Coverage Risk: The company's rental business remains heavily dependent on Medicare and other third-party reimbursement programs. Medicare-related programs accounted for 62.6% of rental revenues in first-quarter 2026, highlighting significant concentration risk. Newer products such as Simeox require broader reimbursement coverage to support adoption. Any unfavorable reimbursement changes or delays in coverage expansion could negatively impact profitability and growth.

Margin Pressure From Cost Inflation and Competition: Inogen remains exposed to inflationary pressures, wage increases, supply chain costs and tariff-related uncertainties. While management does not currently expect a material tariff impact, cost volatility could weigh on margins. International growth also introduces foreign exchange risk, while intense competition in the long-term oxygen therapy market may limit pricing power and constrain profitability as sales shift toward provider channels.

Inogen, Inc Price

Inogen, Inc price | Inogen, Inc Quote

INGN’s Estimate Trend

Inogen has been witnessing a negative estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has expanded by 5 cents to 77 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $369.3 million, suggesting a 5.9% improvement from the year-ago reported number.

Key Picks

Some top-ranked stocks from the broader medical space are BrightSpring Health (BTSG Quick QuoteBTSG - Free Report) , West Pharmaceutical (WST Quick QuoteWST - Free Report) and Globus Medical (GMED Quick QuoteGMED - Free Report) .

BrightSpring Health, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health’s shares have climbed 80.5% against the industry’s 6.7% decline in the year-to-date period.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

West Pharmaceutical’s shares have gained 23.7% against the industry’s 5.1% decline in the year-to-date period.

Globus Medical, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Globus Medical’s shares have lost 6.3% compared with the industry’s 18.3% decline in the year-to-date period.